Diamyd Medical updates on DIAGNODE-2 and upcoming Phase III trial with the diabetes vaccine Diamyd[®]
The database for the European Phase IIb trial DIAGNODE-2 where the diabetes vaccine Diamyd[®] (rhGAD65 / alum) is given directly into the lymph node will be closed within the next few days. As previously announced, the top line results from the trial are expected to be presented at the end of September. The results from DIAGNODE-2 will affect the final design of the upcoming Phase III trial with Diamyd[®] regarding study population and route of administration.When the database has been locked, the code will be broken and the data analyzed by an external statistician. The main results of